Genea Biocells 向美国提供干细胞

jack1381818

在干细胞发表于 2014 年 2 月 18 日
% A& U) a/ j4 L$ P* q6 b, ~% u) j1 p1 c; Y4 T! e
为澳洲干细胞公司Genea Biocells的好处，在国家卫生研究所 (NIH) 人类胚胎干细胞注册表已批准其人类胚胎干细胞系 52 在美国使用。
1 a' d( ]6 S% J8 P7 ~, H3 ^
' J, U+ l# \! ~# }, Z  e Genea 的轻薄行将支持医学研究到严重的遗传或后天疾病，包括孤儿疾病的新疗法。 52 干细胞之间界线与美国国家卫生研究院人类胚胎干细胞登记册所列是 43 特定疾病轻薄代表 24 不同的遗传疾病。
+ B, m' d  a+ P3 n+ u. s2 f4 }* c+ [% B7 I. w7 w
这些遗传疾病包括如亨廷顿病、 结节性硬化症和小儿神经轴索变性，神经退行性条件和 Charcot Marie‐Tooth 疾病、 贝克尔肌营养不良症和强直性肌营养不良症等神经肌肉疾病。
% k& r, g" m3 o% j2 W* {' z" m4 I0 h. H* Y/ a4 B; J6 C
此外包括单元格行表示编码基因的遗传癌症、 代谢类疾病、 血管疾病和眼睛的条件。 核准的九个不受影响的单元格行是从不同遗传背景。0 b) L. z3 m" x, j, F
4 s1 F4 J  ~) r
Genea Biocells 总经理 Uli 施密特说，国家卫生研究院批准的单元格行，完全符合国际道德和监管标准中派生的是承认公司的专门知识和在这一领域的领导。 HESCs 取自胚胎自愿捐赠由患者曾接受体外受精-经常在一起与胚胎植入前遗传学诊断 (PGD)-在 Genea 的生育诊所。也完全知情和自愿同意进行与患者。* f& E3 {  G1 o

* B; ~6 v' ^) m$ L7 _ Genea Biocells， Genea，澳大利亚生育率集团的子公司拥有世界上最大的私人银行的多能干 hESCs 超过 100 个人種細胞株 30 不同的遗传疾病。 美国国家卫生研究院申请剩余 Genea Biocells 单元格行正在准备。8 R/ \* U2 C' [6 L9 i  c# T

; a0 M4 y/ S& [) g, L1 l, P% d原文:$ ?. v/ g1 p( {) E3 r; G2 v1 E
In a boon for Australian stem cell company Genea Biocells, the National Institutes of Health (NIH) Human Embryonic Stem Cell Registry has approved 52 of its human embryonic stem cell lines (hESC) for use in the US. Genea’s hESC lines will support medical research into new treatments for serious genetic or acquired diseases, including orphan diseases. Amongst the 52 stem cell lines listed with the NIH Human Embryonic Stem Cell Registry are 43 disease-specific hESC lines representing 24 different genetic diseases. These genetic diseases include neurodegenerative conditions such as Huntington’s disease, tuberous sclerosis and infantile neuroaxonal dystrophy, and neuromuscular disorders such as Charcot-Marie‐Tooth disease, Becker muscular dystrophy and myotonic dystrophy. Also included are cell lines expressing genes coding for genetic cancers, metabolic conditions, vascular diseases and eye conditions. 
 The nine unaffected cell lines approved are from varied genetic backgrounds. Genea Biocells General Manager Uli Schmidt said the approval by the NIH of the cell lines, which were derived in full compliance with international ethical and regulatory standards, is an acknowledgment of the company’s expertise and leadership in this field. The hESCs are derived from embryos voluntarily donated by patients who have undergone in-vitro fertilisation - often in conjunction with preimplantation genetic diagnosis (PGD) - at Genea’s fertility clinics. A fully informed and voluntary consent process is also conducted with patients. Genea Biocells, a subsidiary of Australian fertility group Genea, has the world’s largest private bank of pluripotent hESCs with more than 100 individual lines representing almost 30 different genetic diseases. NIH applications for remaining Genea Biocells cell lines are in preparation.